L-4899 Lapatinib, Free Base, >99%

Synonyms : [GSK 572016] [GW-572016] [GW 572016X]

Related Terms : [Tykerb] [Tyverb]

  • Size
  • US $
  • £
  • ¥
  • 100 mg
  • 33
  • 29
  • 27
  • 3,500
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 59
  • 53
  • 48
  • 6,300
  • Add to Cart Qty:
  • In stock
  • 300 mg
  • 78
  • 70
  • 64
  • 8,300
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 102
  • 92
  • 83
  • 10,800
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 126
  • 113
  • 103
  • 13,400
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 228
  • 205
  • 187
  • 24,300
  • Add to Cart Qty:
  • In stock
  • 5 g
  • 455
  • 410
  • 374
  • 48,400
  • Add to Cart Qty:
  • In stock
  • 10 g
  • 620
  • 559
  • 510
  • 65,900
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Formal Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Free Shipping and Handling to the U.S. and 33 Other Countries
  • M.W. 581.06
  • C29H26ClFN4O4S
  • [231277-92-2]
  • M.I. 14: 5367

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

Select Lot Number to view Certificate of Analysis

View the SDS for this product

  • More than 720 labs worldwide have purchased Lapatinib or its salt forms from LC Labs (either directly from us or from our many distributors, many of whom resell under their own labels).
  • This is the free base form of lapatinib; please see our product Lapatinib, Di-p-Toluenesulfonate Salt, Cat. No. L-4804, for further technical information. The di-p-toluenesulfonate salt form of lapatinib, not the free base, is used in the lapatinib formulation for use in humans.
  • Lapatinib (as the di-p-toluenesulfonate salt) is the active ingredient in the drug sold under the trade names Tykerb® in the US and Tyverb® in Europe. This drug has been approved in at least one country to treat advanced metastatic breast cancer in conjunction with the chemotherapy drug Xeloda (generic name, capecitabine).
  • The CAS number for Lapatinib, Free Base is given above. The CAS number of the di-p-toluenesulfonate salt (Cat. No. L-4804) is 388082-77-7.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
178